nach oben

Gynäkologische Endokrinologie

Erschienen in:

04.10.2017 | Kohabitationsschmerzen | Menopause und Frauengesundheit

Klinische Relevanz des urogenitalen Syndroms der Menopause

verfasst von: Prof. Dr. med. Ludwig Kiesel, Annemarie Kohl

Erschienen in: Gynäkologische Endokrinologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Auszug

Im Jahr 2014 kam es zur Anpassung des bisher geltenden Terminus durch die International Society for the Study of Women’s Sexual Health (ISSWSH) sowie der Gremien der North American Menopause Society (NAMS). Sie prägten den Begriff des urogenitalen Syndroms der Menopause (engl. „genitourinary syndrome of menopause“ [GSM]), vormals bekannt als vulvovaginale Atrophie (VVA; Abb. 1), urogenitale Atrophie oder atrophische Vaginitis. Der Terminus GSM sei sozial weniger stigmatisierend und solle Patientinnen den offenen Umgang mit der Erkrankung ermöglichen [1]. Im Jahr 2030 werden >17 % der Bevölkerung über 65 Jahre alt sein. Aufgrund der höheren Lebenserwartung von Frauen sind die Konsequenzen postmenopausaler Beschwerden von großem gesellschaftlichem Interesse [2]. …

Portman DJ, Gass ML, Panel VATCC (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause 21(10):1063–1068PubMedCrossRef

Keil K (2002) Urogenital atrophy: diagnosis, sequelae, and management. Curr Womens Health Rep 2(4):305–311PubMed

Palacios S (2009) Managing urogenital atrophy. Maturitas 63(4):315–318PubMedCrossRef

DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J (2015) The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe. J Womens Health (Larchmt) 24(9):713–722CrossRef

Goldstein I (2010) Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 19(3):425–432CrossRef

Willhite LA, O’Connell MB (2001) Urogenital atrophy: prevention and treatment. Pharmacotherapy 21(4):464–480PubMedCrossRef

Nappi RE, Kokot-Kierepa M (2010) Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67(3):233–238PubMedCrossRef

Palacios S, Mejia A, Neyro JL (2015) Treatment of the genitourinary syndrome of menopause. Climacteric 18(Suppl 1):23–29PubMedCrossRef

Mac Bride MB, Rhodes DJ, Shuster LT (2010) Vulvovaginal atrophy. Mayo Clin Proc 85(1):87–94CrossRef

10.

Nappi RE, Panay N, Rabe T, Krychman M, Particco M (Hrsg) (2015) Results of the European REVIVE (Real Women’s VIew of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) survey. 10th Congress of the European Menopause and Andropause Society, Madrid, Spain

11.

Nappi RE, Palacios S, Panay N, Particco M, Krychman ML (2016) Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 19(2):188–197PubMedCrossRef

12.

Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA et al (2013) Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 29(5):437–447CrossRef

13.

North American Menopause Society (2007) The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14(3 Pt 1):351–355

14.

North American Menopause Society (2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 20(9):884–888.

15.

Utian WH (1989) Biosynthesis and physiologic effects of estrogen and pathophysiologic effects of estrogen deficiency: a review. Am J Obstet Gynecol 161(6 Pt 2):1828–1831PubMedCrossRef

16.

Nappi RE, Palacios S (2014) Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 17(1):3–9PubMedCrossRef

17.

Davila GW, Singh A, Karapanagiotou I, Woodhouse S, Huber K, Zimberg S et al (2003) Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 188(2):382–388PubMedCrossRef

18.

Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG (2000) A prospective population-based study of menopausal symptoms. Obstet Gynecol 96(3):351–358 (Sep)PubMed

19.

Bachmann G (2017) SRJ. Clinical manifestations and diagnosis of vaginal atrophy. 6AD. Available from: http://www.uptodate.com/contents/treatment-of-genitourinary-syndrome-of-menopause-vulvovaginal-atrophy. Zugegriffen: 17.09.2017

20.

Castelo-Branco C, Biglia N, Nappi RE, Schwenkhagen A, Palacios S (2015) Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas 81(4):462–469PubMedCrossRef

21.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B et al (2016) Genitourinary syndrome of menopause: evaluation, sequelae, and management. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2016.07.045

22.

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B et al (2016) Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2016.07.045

23.

Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62(4 Suppl 1):45–51PubMedCrossRef

24.

Hyun HS, Park BR, Kim YS, Mun ST, Bae DH (2010) Urodynamic characterization of postmenopausal women with stress urinary incontinence: retrospective study in incontinent pre- and post-menopausal women. J Korean Soc Menopause 16(3):148–152

25.

Luthje P, Hirschberg AL, Brauner A (2014) Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 77(1):32–36PubMedCrossRef

26.

Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M et al (2004) The detection and management of vaginal atrophy. J Obstet Gynaecol Can 26(5):503–515PubMedCrossRef

27.

Stute P (2017) Lokale, nicht-hormonelle Therapie bei postmenopausaler vaginaler Atrophie. Frauenarzt 58(5):394–397

28.

Sinha A, Ewies AA (2013) Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 16(3):305–312PubMedCrossRef

29.

Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23(3):259–263PubMedCrossRef

30.

Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J et al (2015) Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas 82(3):308–313PubMedCrossRef

31.

Edwards D, Panay N (2016) Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 19(2):151–161PubMedCrossRef

32.

Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61(10):3090–3096PubMed

33.

Lev-Sagie A (2015) Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin Obstet Gynecol 58(3):476–491PubMedCrossRef

34.

Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV et al (2014) Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 124(6):1147–1156PubMedPubMedCentralCrossRef

35.

Lethaby A, Ayeleke RO, Roberts H (2016) Local oestrogen for vaginal atrophy in postmenopausal women ( Review ) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd001500.pub3

36.

Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92(4 Pt 2):722–727PubMed

37.

Suckling J, Lethaby A, Kennedy R (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4(4):CD1500

38.

Fischer G, Bradford J (2011) Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis 15(4):263–267PubMedCrossRef

39.

Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA, Manson JED (2017) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. Epub ahead of print

40.

Brockie J (2013) Managing menopausal symptoms: hot flushes and night sweats. Nurs Stand 28(12):48–53PubMedCrossRef

41.

Constantine GD, Goldstein SR, Archer DF (2015) Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 22(1):36–43PubMedPubMedCentralCrossRef

42.

Simon J, Portman D, Mabey RG Jr, Group OS (2014) Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 77(3):274–281PubMedCrossRef

43.

Simon JA, Lin VH, Radovich C, Bachmann GA, Group OS (2013) One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 20(4):418–427PubMed

44.

Paton DM (2014) Ospemifene for the treatment of dyspareunia in postmenopausal women. Drugs Today (barc) 50(5):357–364CrossRef

45.

Bachmann GA, Komi JO, Group OS (2010) Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17(3):480–486PubMed

46.

Berga SL (2013) Profile of ospemifene in the breast. Reprod Sci 20(10):1130–1136PubMedCrossRef

47.

Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD (2015) Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause 22(7):786–796PubMedPubMedCentralCrossRef

48.

Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O et al (2014) Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 17(2):173–182PubMedCrossRef

49.

Moegele M, Buchholz S, Seitz S, Ortmann O (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 285(5):1397–1402PubMedCrossRef

50.

Panjari M, Davis SR (2011) Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 70(1):22–25PubMedCrossRef

51.

Baumgart J, Nilsson K, Stavreus-Evers A, Kask K, Villman K, Lindman H et al (2011) Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 204(1):26.e1–26.e7CrossRef

52.

Dew JE, Wren BG, Eden JA (2003) A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6(1):45–52PubMedCrossRef

53.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L et al (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23(3):243–256PubMedCrossRef

54.

Hutchinson-Colas J, Segal S (2015) Genitourinary syndrome of menopause and the use of laser therapy. Maturitas 82(4):342–345PubMedCrossRef

55.

Stefano S, Stavros A, Massimo C (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27(6):504–508PubMed

56.

Abrahamse H (2012) Regenerative medicine, stem cells, and low-level laser therapy: future directives. Photomed Laser Surg 30(12):681–682PubMedCrossRef

57.

Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N et al (2015) Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy. Climacteric 18(2):219–225PubMedCrossRef

58.

Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M et al (2014) A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 17(4):363–369PubMedCrossRef

59.

Gambacciani M, Levancini M, Cervigni M (2015) Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 18(5):757–763PubMedPubMedCentralCrossRef

60.

Vicariotto F, Raichi M (2016) Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device. Minerva Ginecol 68(3):225–236PubMed

61.

Nicoletti G, Cornaglia AI, Faga A, Scevola S (2014) The biological effects of quadripolar radiofrequency sequential application: a human experimental study. Photomed Laser Surg 32(10):561–573PubMedPubMedCentralCrossRef

62.

Mendoza N, Abad P, Baro F, Cancelo MJ, Llaneza P, Manubens M et al (2013) Spanish Menopause Society position statement: use of tibolone in postmenopausal women. Menopause 20(7):754–760PubMedCrossRef

63.

Al-Saqi SH, Uvnas-Moberg K, Jonasson AF (2015) Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health 21(3):88–97PubMedPubMedCentralCrossRef

Titel: Klinische Relevanz des urogenitalen Syndroms der Menopause
verfasst von: Prof. Dr. med. Ludwig Kiesel
Annemarie Kohl
Publikationsdatum: 04.10.2017
Verlag: Springer Medizin
Schlagwörter: Kohabitationsschmerzen
Urogenitales Menopausensyndrom
Östrogene
Erschienen in: Gynäkologische Endokrinologie / Ausgabe 4/2017
Print ISSN: 1610-2894
Elektronische ISSN: 1610-2908
DOI: https://doi.org/10.1007/s10304-017-0155-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Pubertätsstörungen beim Mädchen

Einfluss einer Hormonersatztherapie auf das Risiko eines malignen Melanoms

Hydrosalpinx

Einfluss von Atosiban auf die Erfolgschancen von In-vitro-Ferilisation